FDA Authorizes Reduced-Risk Claims for 20 Zyn Nicotine Pouch Products

The U.S. Food and Drug Administration (FDA) has issued Modified Risk Tobacco Product (MRTP) orders for 20 Zyn nicotine pouch products manufactured by Swedish Match USA, according to a report by Tobacco Reporter on June 30, 2026. This decision marks Zyn as the first nicotine pouch brand to receive authorization to market reduced-risk claims compared with cigarettes. The authorization applies to 10 Zyn flavors across both 3 mg and 6 mg nicotine strengths.

The FDA-authorized claim states that using Zyn instead of cigarettes lowers the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis. The agency's decision followed an extensive scientific review, which assessed the products’ relative health risks, consumer understanding of the claims, youth use data, and overall population health impact. The FDA concluded that the modified-risk claim is scientifically supported, understood by consumers, and is expected to benefit public health. Swedish Match USA is required to conduct post-market surveillance and behavioral studies, with the orders set to expire after five years unless renewed. The FDA retains the authority to withdraw the orders if public health benefits diminish, including due to increased youth uptake.

Philip Morris International (PMI) confirmed the FDA's decision, stating it expands the company's portfolio of FDA-authorized modified-risk products, which also includes IQOS heated tobacco products and General snus. According to a press release from pmi.com, PMI U.S. CEO Stacey Kennedy commented that the authorization provides adult nicotine consumers with FDA-reviewed, science-based information regarding the health benefits of switching completely from cigarettes to Zyn. Kennedy further emphasized that this decision is a significant moment for the more than 45 million legal-age nicotine consumers in America, reinforcing the agency's science-based approach to evaluating products across the continuum of risk.

This authorization builds upon Zyn's prior authorization for sale through the FDA’s premarket tobacco product application pathway in January 2025. The FDA's rigorous review process, which included evaluating potential impacts on youth and overall population health, underscores the agency's commitment to a public health standard for tobacco product regulation. The requirement for ongoing post-market surveillance highlights the conditional nature of these authorizations, ensuring continuous monitoring of real-world effects. This development could set a precedent for future regulatory evaluations of modern oral nicotine products within the U.S. market.